Navigation Links
Teriparatide outperforms alendronate in treating steroid-induced osteoporosis
Date:10/28/2009

A recent study determined glucocorticoid-induced osteoporosis (OP) is now treatable with Teriparatide, a synthetic form of the human parathyroid hormone. Researchers found patients with glucocorticoid-induced OP who were treated with teriparatide for 36 months had a greater increase in bone mineral density (BMD) and fewer new vertebral fractures than those treated with alendronate. The findings of this study are published in the November issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR).

Glucocorticoids are steroid hormones that are naturally produced in the body or synthetically created compounds (drugs) used to reduce inflammation. These steroid drugs are used to control inflammation in patients with such autoimmune diseases as rheumatoid arthritis, systemic lupus erythematosus, and Crohn's disease as well as inflammatory conditions such as asthma. Glucocorticoid-induced osteoporosis occurs when patients taking steroid medications such as prednisone, prednisolone, dexamethasone, and cortisone exhibit reduced bone mass and bone strength.

This 36-month, randomized, double-blind, controlled trial, led by Kenneth Saag, M.D., from the University of Alabama, was conducted at 76 centers located in 13 countries. A total of 428 patients between the ages of 22-89 with confirmed OP who had received greater than 5 mg/day of prednisone or equivalent for more than 3 months preceding screening were included. Research measures included changes in lumbar spine and hip bone, BMD, changes in bone biomarkers, fracture incidence, and safety.

Study participants were randomly assigned to receive injectable teriparatide (20 μg/day) plus oral placebo (150 subjects) or oral alendronate (10 mg/day) plus injectable placebo (144 subjects). Supplements of calcium (1,000 mg/day) and vitamin D (800 IU/day) were provided to all study participants. Subjects kept a daily journal to record their steroid use.
'/>"/>

Contact: Dawn Peters
medicalnews@wiley.com
781-388-8408
Wiley-Blackwell
Source:Eurekalert

Page: 1 2

Related medicine news :

1. FDA Approves Expanded Use of Lillys FORTEO(R) [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis
2. Cheap, quick bedside eye movement exam outperforms MRI for diagnosing stroke in patients
3. New heart disease risk score outperforms existing test
4. Molecular Breast Imaging Outperforms MRI for Patients With Inconclusive Results in the Diagnosis of Cancer
5. MedAmerica Reports Solid Growth, Outperforms Industry
6. PET outperforms CT in characterization of lung nodules
7. COURAGE Sub-study: PCI Outperforms Drugs-Only
8. Watson to Distribute Alendronate Tablets
9. Stanford study recommends change in treating pulmonary embolisms
10. Oklahoma scientists discover promising new path for treating traumas
11. Treating ROP in tiny preemies; better glaucoma follow-up in urban clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... (HealthDay News) -- Daily supplements of selenium or vitamin ... of age-related cataracts among men, a new study indicates. ... both could help prevent cataracts. To investigate this further, ... Medical School in Boston, and his colleagues examined data ... E. The trial was initially designed to study prevention ...
(Date:9/18/2014)... (CHEST) together with the Chinese Thoracic Society (CTS) ... that CHEST World Congress 2016 will be held ... and sleep medicine from around the world are ... spring 2016. , CHEST World Congress 2016 ... training, keynote addresses, presentations by leading health-care experts, ...
(Date:9/18/2014)... NJ (PRWEB) September 18, 2014 ... firm, announced today that President and co-founder John ... Journal’s Innovation Award Winners for 2014, recognizing the ... him as an emerging executive of the year. ... care and life sciences that continue to shape ...
(Date:9/18/2014)... Qualis Health, one of the nation’s ... white paper, “Advancing Primary Care through the Patient-Centered Medical ... , Authors Jeff Hummel, MD, MPH and Peggy C. ... engaged in the work of becoming a Patient-Centered Medical ... PCMH objectives, such as generating and providing useful data ...
(Date:9/18/2014)... 2014 Stealth Health Revolution co-founders, ... and Frank Davis, founder of Food for Health ... pleased to announce the new recipe book, "The ... nutrition-packed meals using Activz whole-food powders." The ... in the Stealth Health Revolution mission ...
Breaking Medicine News(10 mins):Health News:Vitamin E, Selenium Supplements Don't Seem to Prevent Cataracts 2Health News:CHEST announces China as site of CHEST World Congress 2016 2Health News:TayganPoint Executive Receives Prestigious Award from Philadelphia Business Journal 2Health News:Advancing Primary Care Through PCMH and HIT: New White Paper Connects the Dots 2Health News:Montel Williams and Frank Davis Announce New Whole-Food Nutrition Recipe Book, The Simple Scoop, at Natural Products Expo East In Baltimore 2Health News:Montel Williams and Frank Davis Announce New Whole-Food Nutrition Recipe Book, The Simple Scoop, at Natural Products Expo East In Baltimore 3
... released today by the Association for Psychological Science: , , ... 65; in 2000 that number had jumped to 12.6 percent; and ... in that category. , , Cognitive decline was long ... seen a surge of interest in activities and products touted to ...
... Arcadia Resources, Inc. (NYSE Amex: KAD ... and pharmacy services under the Arcadia HealthCare(SM) brand, has ... Co., as Vice President of DailyMed(TM) Pharmacy Operations , ... the Indianapolis pharmacy operations, manage system integration within DailyMed ...
... Region recognizes immediate, ... ... Center and CHRISTUS St. Vincent Medical Group in Santa Fe, New Mexico, through teamwork, focused ... in nine months. CHRISTUS Health began managing CHRISTUS St. Vincent in April 2008 and ...
... health communications company StayWell Custom Communications (SCC), a division ... Grocer magazine to publish the white paper ... the Economy" to spotlight the retail sector,s growing need ... , , The white paper is a ...
... to include " Oncology Therapeutic ... , , - Center will train pharmacists to specialize in ... 23 Medco Health Solutions, Inc. (NYSE: MHS ), joined ... at AllPoints at Anson will house the Medco Therapeutic Resource Center(R) ...
... diagnostics market is poised for expansion with segments such ... potential. Heightened efforts to generate awareness about diabetes and ... development. For instance, limited awareness about HbA1C tests is ... curtailed with more education about the test. , ...
Cached Medicine News:Health News:Major New Report Establishes Effective Methods of Enhancing and Preserving Brain Power as We Age 2Health News:Major New Report Establishes Effective Methods of Enhancing and Preserving Brain Power as We Age 3Health News:Arcadia HealthCare Names Former Walgreen's Executive Charles Goodall as Vice President of DailyMed(TM) Pharmacy Operations 2Health News:Arcadia HealthCare Names Former Walgreen's Executive Charles Goodall as Vice President of DailyMed(TM) Pharmacy Operations 3Health News:Arcadia HealthCare Names Former Walgreen's Executive Charles Goodall as Vice President of DailyMed(TM) Pharmacy Operations 4Health News:CHRISTUS Health New Mexico Region Focuses on Cost Management; Saves $1.8 Million 2Health News:CHRISTUS Health New Mexico Region Focuses on Cost Management; Saves $1.8 Million 3Health News:Pivotal White Paper Examines Retail Industry's Critical Role in Reengineering the Health Care System 2Health News:Pivotal White Paper Examines Retail Industry's Critical Role in Reengineering the Health Care System 3Health News:Medco's Advanced Pharmacy Adds 162 New Jobs for Total of 1,400 2Health News:Medco's Advanced Pharmacy Adds 162 New Jobs for Total of 1,400 3Health News:Frost & Sullivan: Self-Monitoring and POC Diabetes Tests Reveal Potential for Significant Growth, Boosting the European Diabetes Diagnostics Market 2Health News:Frost & Sullivan: Self-Monitoring and POC Diabetes Tests Reveal Potential for Significant Growth, Boosting the European Diabetes Diagnostics Market 3
(Date:9/18/2014)... Sept. 18, 2014  Zacks.com announces the list of ... Zacks Equity Research analysts discuss the latest news and ... featured in the blog include the Avanir Pharmaceuticals (Nasdaq: ... NPSP - Free Report ), Orexigen (Nasdaq: OREX ... Free Report ) and Gilead (Nasdaq: GILD - ...
(Date:9/18/2014)... DIEGO , Sept. 18, 2014  Halozyme ... announced that the U.S. Food and Drug Administration ... enrollment and dosing of PEGPH20 in SWOG,s ongoing ... designed to evaluate Halozyme,s investigational drug PEGPH20 (PEGylated ... chemotherapy (mFOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma.  ...
(Date:9/18/2014)... After 6 months of careful research ... - the new programme for the next Cool Chain & ... global Cool Chain series, has just been released! ... As the lines between supply chain, logistics, QA and purchasing ... is broad and yet specific, focused and yet accessible, inclusive ...
Breaking Medicine Technology:The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 2The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 3The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 4The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 5The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 6SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 2SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 3SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 4Europe's Biggest and Longest-Running Gathering of Life Sciences Logistics, Supply Chain & QA Professionals 2
... VIEW, Calif., Dec. 21, 2010 MAP Pharmaceuticals, Inc. (Nasdaq: ... ™ open-label safety trial.  The Company has now completed ... (NDA) for LEVADEX and plans to submit an NDA in ... inhaled migraine therapy that has completed Phase 3 clinical development ...
... -- China Botanic Pharmaceutical Inc. (AMEX: CBP ... and distributor of botanical products, bio-pharmaceuticals and traditional Chinese ... considerable progress in its efforts to comply with the ... 404") for fiscal year 2010. As announced ...
Cached Medicine Technology:MAP Pharmaceuticals Announces Completion of LEVADEX™ Open-Label Safety Trial 2MAP Pharmaceuticals Announces Completion of LEVADEX™ Open-Label Safety Trial 3China Botanic Announces Progress on its SOX 404 Compliance Program 2China Botanic Announces Progress on its SOX 404 Compliance Program 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: